CHI3L1 and in situ carcinoma: Several studies have also shown that CIS patients with higher CSF CHI3L1 levels faster convert to clinically definite MS, suggesting that CHI3L1 might be a prognostic biomarker for disease activity and disability progression in the early stages of multiple sclerosis [70,71,73,78,92,93].